Abstract
PURPOSE The Mini-Mental State Examination (MMSE) is one of the most widely used instruments to screen for cognitive deficits; however, this instrument alone is not sensitive enough to detect early symptoms of dementia. We aimed to investigate whether additionally using the Visual Association Test (VAT) improves the predictive value of the MMSE score for development of dementia.
METHODS Analyses were based on data from 2,690 primary care patients aged 70 to 78 years who participated in the Prevention of Dementia by Intensive Vascular Care (preDIVA) trial. We assessed change in the 30-point MMSE score over 2 years and the VAT score at 2 years—dichotomized as perfect (6 points) or imperfect (≤5 points)—and evaluated the predictive values of these tests for a diagnosis of dementia in the subsequent 4 to 6 years. Data were analyzed with logistic regression analysis.
RESULTS Patients having a decline of 2 points or more in total MMSE score over 2 years had an odds ratio of 3.55 (95% CI, 2.51–5.00) for developing dementia. Patients having the same decline in MMSE score plus an imperfect VAT score had an odds ratio of 9.55 (95% CI, 5.89–15.41) for developing dementia. A 1-point decline in MMSE score increased odds of dementia only when the VAT score was imperfect. Dementia risk for patients with a 2- or 3-point decrease in MMSE score and a perfect VAT score did not differ significantly from the average risk of the cohort as a whole.
CONCLUSIONS Administering the VAT in patients with a small decline on the MMSE over a 2-year period has substantial incremental value for identifying those at elevated risk for developing dementia. This simple test may help distinguish older adults who need further cognitive examination from those in whom a watchful waiting policy is justified.
Footnotes
Conflicts of interest: authors report none.
Author contributions: W.A.vG. designed the study. S.J. conducted the statistical analysis and literature search and wrote the article. All authors contributed intellectually to the writing or revising of the manuscript, and approved the final version.
Trial registration: The preDIVA trial is registered with ISRCTN, number ISRCTN29711771.
Supplementary materials: Available at http://www.AnnFamMed.org/content/16/3/206/suppl/DC1/.
Funding support: The preDIVA study was funded by the Dutch Ministry of Health, Welfare and Sport; Dutch Innovation Fund of Collaborative Health Insurances; and Netherlands Organisation for Health Research and Development.
- Received for publication June 6, 2017.
- Revision received December 16, 2017.
- Accepted for publication January 18, 2018.
- © 2018 Annals of Family Medicine, Inc.